Sanket Koul

India logs 164 new Covid-19 cases in one week, active cases cross 250

India records 164 new Covid-19 cases between May 12 and 19, with Kerala, Tamil Nadu and Maharashtra reporting most cases; officials say symptoms remain mild

IHH subsidiary seeks Rs 11,800 cr damages from Daiichi over Fortis deal

IHH arm NTK raises damages claim against Daiichi Sankyo to Rs 11,800 crore, alleging obstruction of Fortis Healthcare acquisition via stalled open offer

DLF records highest-ever sales in FY25 on super luxury housing boom

Projects like The Dahlias and Privana West fuelled DLF's FY25 sales to a record Rs 21,223 crore, with strong demand from domestic buyers and NRIs

Max Healthcare Q4 net profit rises 26.8% to Rs 319 crore, revenue up 32%

Profit growth driven by higher occupancy, rising Arpob, international patient inflow and new bed additions across Lucknow, Dwarka and BLK Max facilities

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar

Bhutani Infra, Yashoda Hospitals in ₹1,000 cr JV for Noida project

Fully AI-integrated project in Greater Noida

DLF Q4FY25 results: Net profit rises 39% to ₹1,282 crore; revenue up 46%

DLF posts robust Q4FY25 results with 39% rise in profit and 46% growth in revenue, driven by record sales from luxury projects and steady rental performance

Govt holds review meetings to monitor Covid-19 situation in India

Govt says Covid-19 situation remains under control despite a minor uptick in cases, amid rising infections in Singapore and Hong Kong attributed to Omicron subvariants

Covid-19 spike in Hong Kong, Singapore not yet a concern for India: Experts

Doctors advise calm as India sees just 58 new Covid-19 cases amid a rise in HK and Singapore; experts highlight low hospitalisation and no serious strain currently

Capacit'e eyes Middle East market after Maldives foray, cites growth

Data centres and hospitals are key growth drivers for EPC firm Capacit'e Infraprojects as it enters global markets after its first international project in Maldives

Signature Global may launch NCR projects worth ₹17,000 crore in FY26

Firm looks to stay in its core mid-size project segment

Medanta Q4 PAT falls 20%, revenue rises 15% on strong patient volume

Global Health reports Q4FY25 PAT drop to ₹101.4 crore on one-time expense; revenue up 15% to ₹931.2 crore; expansion plans include 550-bed Noida facility by FY26

Signature Global Q4 results: Net profit rises 48%, revenue down 25%

Realty firm Signature Global saw a record ₹10,290 crore in FY25 pre-sales despite a Q4 revenue decline caused by project launch delays due to pending approvals

After JNU, Jamia suspends MoU with Turkish institutions citing security

Jamia Millia Islamia suspends all MoUs with institutions linked to Turkiye, joining JNU and CSJM in response to growing concerns over national security and diplomacy

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

Sanofi India Q4 results: Profit falls 12.5% to ₹119.5 cr, revenue up 4.9%

Sanofi India's Q4FY25 profit declined 12.5% Y-o-Y to ₹119.5 crore, while revenue rose 4.9%; operating profit improved 27% on better efficiency, says CFO

PM Modi calls for scaling up early detection to eliminate TB by 2025

India accounts for 26 per cent of global TB burden; PM highlights technology use, infrastructure expansion and targeted outreach as key to meeting 2025 goal

CBSE Class 10, 12 pass percentages up slightly, still below 2022 peak

Pass percentages for CBSE Class 10 and 12 rose marginally this year to 93.66 per cent and 88.39 per cent respectively, but remained lower than 2022 levels

Trump Residences in Gurugram sells out in a day for Rs 3,250 crore

Apartments priced between Rs 8 crore and Rs 15 crore, with four penthouses at Rs 125 crore each, fully allotted in second Trump-branded project in Gurugram

GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches including Zejula and Jemperli on track